Table 3 Mean (95% CI) scores and treatment effect (differences between baseline and post-treatment, 3 weeks after intervention) *
SMP group | Control group | Treatment effect (95 CI) | P value | Effect size§ | |
|---|---|---|---|---|---|
Primary outcomes: | |||||
Psychological distress (GHQ20) (0 - 60, 0 = no distress) | 0.552 | ||||
Baseline | 27.0 (11.0-57.2) | 26.4 (10.0-50.2) | |||
Post-treatment | 25.0 ( 6.0-49.1) | 24.6 (10.0-57.2) | 0.96 (-2.2 to 4.1) | 0.10 | |
Effective Musculoskeletal Consumer Scale (EC-17) (0 -100 , 0 = never, 100 = always) | 0.016 | ||||
Baseline | 57.5 (22.1-88.2) | 54.3 (0.0-86.8) | |||
Post-treatment | 63.0 (36.8-97.1) | 56.8 (1.5-100) | 4.26 (0.8 to 7.7) | 0.24 | |
Secondary outcomes: | |||||
Self-efficacy pain (10 - 100, 100 = high SE) | 0.387 | ||||
Baseline | 50.6 (18.0-82.0) | 51.4 (10.0-98.0) | |||
Post-treatment | 54.8 (16.0-94.0) | 52.3 (10.0-82.0) | -1.83 (-6.0 to 2.3) | 0.12 | |
Self-efficacy symptoms (10 - 100, 100 = high SE) | 0.189 | ||||
Baseline | 57.8 (20.0-93.3) | 57.7 (11.7-86.7) | |||
Post-treatment | 61.4 (35.0-91.7) | 57.9 (23.3-90.0) | 2.63 (-1.3 to 6.6) | 0.20 | |
Self –efficacy function (10-100, 100 = high SE) | 0.556 | ||||
Baseline | 77.9 (22.2-100.0) | 74.7 (18.9-100.0) | |||
Post-treatment | 77.9 (32.2-100.0) | 72.8 (16.7-100.0) | 1.02 (-2.4 to 4.4) | 0.06 | |
Fibromyalgia Impact Questionnaire (0-10, 0 = low impact) | 0.265 | ||||
Baseline | 59.0 (16.1-89.6) | 59.7 (23.9-92.5) | |||
Post-treatment | 55.9 (7.0-90.5) | 61.0 (23.2-93.2) | -2.76 (-7.7 to 2.1) | 0.15 | |